RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.
  3. Financials
  4. Operating income

Citius Pharmaceuticals, Inc.CTXR

Market cap
$10.7M
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Sep 30, 2024-42+14.33%
Sep 30, 2023-37+10.25%
Sep 30, 2022-33+41.58%
Sep 30, 2021-24+32.87%
Sep 30, 2020-18+13.54%
Sep 30, 2019-16+13.12%
Sep 30, 2018-14+38.08%
Sep 30, 2017-10+34.06%
Sep 30, 2016-7+130.63%
Sep 30, 2015-3+11387.05%
Sep 30, 2013-0+43.33%
Sep 30, 2012-0-23.48%
Sep 30, 2011-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)